[Skip to Content]
[Skip to Content Landing]
Views 256
Citations 0
Research Letter
July 10, 2017

Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder

Author Affiliations
  • 1Tianjin Neurological Institute, Department of Neurology, Tianjin Medical University General Hospital, Tianjin, China
  • 2Barrow Neurological Institute, Division of Neurology, St Joseph's Hospital and Medical Center, Phoenix, Arizona
JAMA Neurol. Published online July 10, 2017. doi:10.1001/jamaneurol.2017.1336

In neuromyelitis optica spectrum disorder (NMOSD), enhanced plasma cell activity contributes to antiaquaporin-4 autoantibody (AQP4-ab) production.1 Longitudinal data indicate that 25% to 66% of patients with NMOSD who are treated with azathioprine, rituximab, and other immune-modifying therapies still experience relapses.2 Here we assess the safety and efficacy of bortezomib, a selective inhibitor of the 26S proteasome subunit, among patients with highly relapsing NMOSD.

First Page Preview View Large
First page PDF preview
First page PDF preview